Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
April 08, 2024
When Gavi, the Vaccine Alliance, was founded in 2001, it logically targeted its support to the poorest countries—with GNI per capita under a pre-defined eligibility threshold—that also had the highest shares of the world’s undervaccinated children. Fast-forward almost 25 years, and the situation has...
Blog Post
April 08, 2024
Gavi is facing several important milestones in 2024: developing its next five-year strategy, known as “Gavi 6.0,” gearing up for its upcoming replenishment, and welcoming its new CEO. This year presents an opportunity for Gavi’s board and leadership to revisit its approach to ensure continued impact...
Blog Post
March 18, 2024
Today, Dr. Sania Nishtar assumes her role as Gavi's new CEO. A lot has changed—both within Gavi and in the external environment—since the process began to replace Dr. Seth Berkley, who stepped down last year. Dr. Nishtar’s appointment comes at a critical time for Gavi. As CEO, Dr. Nishtar will play ...
Blog Post
December 14, 2023
Harsh fiscal prospects and broader shifts in the health landscape are creating challenges for Gavi’s approach to country eligibility and transition. To date, Gavi’s income-based eligibility model has functioned well during periods of sustained growth in low- and middle-income countries and has helpe...
Blog Post
December 04, 2023
In the aftermath of the COVID-19 pandemic, Gavi faces an unprecedented situation. Billions of dollars that it raised back in 2022 for COVAX—the global effort to provide COVID-19 vaccines to lower-income countries—remain unspent. These resources are substantial, exceeding the entire annual budget of ...
Blog Post
December 01, 2023
When Gavi’s board meets in Accra, Ghana, next week, advancing discussions on a new five-year strategic period, known as “Gavi 6.0,” will be a top agenda item. But conversations about Gavi’s future direction are also taking place against the backdrop of a leadership transition and a rapidly changing ...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.